Total trials
261
Active
43
Phase 3
6
Total enrollment
54,966
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 11 of 11 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Apixaban 2.5 mg twice daily | — | — | — | — | — | 1 | |
| Apixaban 5 mg once daily | — | — | — | — | — | 1 | |
| No anticoagulation | — | — | — | — | — | 1 | |
| Gemcitabine Delivered by Transarterial Microperfusion | — | — | — | — | — | 1 | |
| Apixaban | — | — | — | — | — | 1 | |
| Pyridostigmine Bromide | — | — | — | — | — | 1 | |
| oxaliplatin | — | — | — | — | — | 1 | |
| Fluoropyrimidine | — | — | — | — | — | 1 | |
| Fezolinetant | — | — | — | — | — | 1 | |
| cisplatin | — | — | — | — | — | 2 | |
| Dexamethasone plus Venetoclax-based Low-Intensity Therapy | — | — | — | — | — | 1 |
Next readouts
- 2026-11
- 2026-12-30
- 2026-12-31
- 2027-01
- 2029-03-01
- 2029-06
- 2030-07-01
- 2030-12
- 2035-08
Top conditions
- Obesity17
- Tobacco Use Disorder10
- Breast Cancer9
- Opioid-Related Disorders8
- Asthma7
- Cancer6
- Smoking Cessation6
- Overweight4
Frequently asked questions about University of Vermont
- How many clinical trials does University of Vermont have on ClinicalTrials.gov?
- University of Vermont is listed as the lead sponsor on 261 clinical trials in ClinicalTrials.gov, 43 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Vermont's trials are in Phase 3?
- 6 of University of Vermont's trials are in Phase 3, spread across 11 active drug programs.
- What therapeutic areas does University of Vermont focus on?
- University of Vermont's most-studied conditions on ClinicalTrials.gov are Obesity, Tobacco Use Disorder, Breast Cancer, Opioid-Related Disorders, Asthma.
- When are University of Vermont's next clinical trial readouts?
- University of Vermont has 9 upcoming primary-completion readouts tracked here; the soonest is “Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies”, expected around 2026-11.